ARPO Aerpio Pharmaceuticals Inc

DGAP-News: One Square Advisory Services GmbH: publity AG - Vote without meeting of the bondholders of the convertible bond 2015/2020

DGAP-News: One Square Advisory Services GmbH / Key word(s): Bond/Capital Reorganisation
One Square Advisory Services GmbH: publity AG - Vote without meeting of the bondholders of the convertible bond 2015/2020

19.02.2019 / 19:53
The issuer is solely responsible for the content of this announcement.


Munich, 19. February 2019 - publity AG published the following ad hoc announcement on 18. February 2019 (English convenience translation only):

"publity AG calls for a vote of the bondholders of the convertible bond 2015/2020

Frankfurt, 18. February 2019 - In its Corporate News, dated 28. January 2019, publity AG announced that it is considering options to raise debt capital for the possible issuance of a new bond. These reviews are still ongoing.

However, the prerequisite for raising new financing is in any case dependent on a negative pledge defined in the terms and conditions of the publity AG convertible bond 2015/2020, according to which publity AG may not enter such financial indebtedness in an amount of more than EUR 5,000,000.00, being amended.

publity AG therefore today called for a bondholder vote of the convertible bond 2015/2020 to amend the bond terms accordingly. In return, the bondholders are to be granted the right to demand an early repayment from the issuer of either individual or all their bonds plus accrued interest if the issuer enters into a new financial liability of more than EUR 5 million.

The invitation to vote has been published today in the electronic federal gazette (Bundesanzeiger)."

One Square Advisory Services GmbH ("One Square"), in its capacity as joint representative of the EUR 50 million, 2015/2020, 3.500% convertible bonds issued by publity AG (the "Convertible Bond", ISIN: DE000A169GM5/ WKN: A169GM), has negotiated the proposed resolutions with the Company, reviewed these and identified significant advantages for the bondholders and advocates this procedure.

In order to ensure that the holders of the convertible bond can potentially participate in an early repayment at par and accrued interest, the joint representative calls upon the bondholders to agree to the agenda items. For this purpose, a presence of at least 50% of the outstanding convertible bond and a majority of at least 75% of the voting rights participating in the vote are required in the voting without a meeting, beginning on Tuesday, 12. March 2019, at 0:00h (CET) and ending on Thursday, 14. March 2019, at 24:00h (CET).

The necessary documents to participate in the voting without a meeting can be downloaded from the issuer's website () under the heading "Investor Relations" under the section "Convertible Bonds".

One Square will inform the bondholders about further developments and is available for queries, at . Bondholders of the Convertible Bond who are not yet registered are invited to register on One Square's homepage at .

Contact:
One Square Advisory Services GmbH
Theatinerstr. 36
80333 Munich
fax          2
email    
web      


19.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


777833  19.02.2019 

fncls.ssp?fn=show_t_gif&application_id=777833&application_name=news&site_id=research_pool
EN
19/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch